Past information
- Jun Sasaki, President and CEO of Rena Therapeutics Inc. made a presentation at “Nucleic Acids Therapeutics Society of Japan” held in Kyushu.
July 9, 2018 - Jun Sasaki, President and CEO of Rena Therapeutics Inc. gives a presentation at Network Night” held by INCJ.
May 10, 2018 - Exhibited the panel at INCJ booth in BioJapan2017 held in PACIFICO Yokohama for introducing our business and technology
October 11-13, 2017
- Participated in 3rd Annual Meeting of the Nucleic Acids Therapeutics Society of Japan in Hokkaido
July 12-14, 2017 - Announcement on Completion of Issue of New Shares through Third-Party Allotment
June 30, 2017 - Participated in BIO International Convention 2017 in San Diego, California
June 19-22, 2017 - Our platform Hetero-Duplex Oligonucleotide Technology’s basic patent was registered in Japan(Patent No.JP6112569)
March 24, 2017 - Made a presentation at “BioAsia2017” held in Roppongi Tokyo, co-hosted by BioCentury and JBA(Japan Bioindustry Association)
March 15, 2017 - Made a presentation at “Biotechnology-related industry matching meeting & presentation at Nihonbashi” hosted by Kanto Bureau of Economy, Trade and Industry, METI
January 26, 2017 - Rena Therapeutics Inc. marked the second anniversary
January 15, 2017 - Junichi Yano was appointed Chairman, and Jun Sasaki was appointed President & CEO
December 15, 2016 - Exhibited the panel at INCJ booth in BioJapan2016 held in PACIFICO Yokohama for introducing our business and technology
October 12-14, 2016 - Press conference
August 7, 2015 - Series A funding from Innovation Network Corporation of Japan, DBJ Capital Co., Ltd. and KSP Inc. is completed
April 20, 2015 - Granted university ventures honor from Tokyo Medical and Dental University
February 25, 2015 - Rena Therapeutics Inc. founded
January 15, 2015